Patents Assigned to TEIKYO HEISEI UNIVERSITY
  • Recombinant obligate anaerobic Gram-positive bacteria
    Patent number: 10882912
    Abstract: An object of the present invention is to effectively induce cancer cell apoptosis using the anti-TRAIL-R1 antibody(ies) and the anti-TRAIL-R2 antibody(ies) and to reduce the toxicity imposed on normal cells. The present invention relates to recombinant obligate anaerobic Gram-positive bacteria that include a nucleic acid encoding a fusion protein having 3 or more anti-TRAIL-R1 single-chain antibodies and/or 3 or more anti-TRAIL-R2 single-chain antibodies, in an expressible state.
    Type: Grant
    Filed: February 19, 2019
    Date of Patent: January 5, 2021
    Assignee: TEIKYO HEISEI UNIVERSITY
    Inventors: Takeshi Nishikawa, Yuichiro Taira, Ikuko Taira, Isao Ishida
  • RECOMBINANT OBLIGATE ANAEROBIC GRAM-POSITIVE BACTERIA
    Publication number: 20190169305
    Abstract: An object of the present invention is to effectively induce cancer cell apoptosis using the anti-TRAIL-R1 antibody(ies) and the anti-TRAIL-R2 antibody(ies) and to reduce the toxicity imposed on normal cells. The present invention relates to recombinant obligate anaerobic Gram-positive bacteria that include a nucleic acid encoding a fusion protein having 3 or more anti-TRAIL-R1 single-chain antibodies and/or 3 or more anti-TRAIL-R2 single-chain antibodies, in an expressible state.
    Type: Application
    Filed: February 19, 2019
    Publication date: June 6, 2019
    Applicant: TEIKYO HEISEI UNIVERSITY
    Inventors: Takeshi Nishikawa, Yuichiro Taira, Ikuko Taira, Isao Ishida
  • Recombinant obligate anaerobic gram-positive bacteria
    Patent number: 10266601
    Abstract: An object of the present invention is to effectively induce cancer cell apoptosis using the anti-TRAIL-R1 antibody(ies) and the anti-TRAIL-R2 antibody(ies) and to reduce the toxicity imposed on normal cells. The present invention relates to recombinant obligate anaerobic Gram-positive bacteria that include a nucleic acid encoding a fusion protein having 3 or more anti-TRAIL-R1 single-chain antibodies and/or 3 or more anti-TRAIL-R2 single-chain antibodies, in an expressible state.
    Type: Grant
    Filed: December 24, 2014
    Date of Patent: April 23, 2019
    Assignee: TEIKYO HEISEI UNIVERSITY
    Inventors: Takeshi Nishikawa, Yuichiro Taira, Ikuko Taira, Isao Ishida